Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Steven Berman

Interventional Pain Medicine Reno, NV Medical Doctor

NPI 1720013055 CMS profile 123482

605 Sierra Rose Dr, Suite 4, Reno, NV 89511

Open in the dashboard

General payments

$25,254

654 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Steven Berman of Reno, NV is reported in the CMS Open Payments database as having received $25,254 across 654 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 88th percentile of Interventional Pain Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,821 77
2024 General $1,447 53
2023 General $10,843 67
2022 General $2,394 99
2021 General $2,348 95
2020 General $3,875 107
2019 General $2,525 156

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Steven Berman
  • Interventional Pain Medicine median
  • Middle half of Interventional Pain Medicine
  • National median

In program year 2025, general payments to Steven Berman were reported at $1,821. Among 1,891 Interventional Pain Medicine profiles paid that year, the median was $657 and the middle half received between $184 and $1,753.

Show as a table
Year Steven Berman Interventional Pain Medicine median Middle half National median
2019 $2,525 $684 $216–$2,079 $163
2020 $3,875 $382 $122–$1,109 $114
2021 $2,348 $552 $167–$1,554 $132
2022 $2,394 $605 $187–$1,924 $149
2023 $10,843 $671 $195–$1,915 $160
2024 $1,447 $684 $206–$1,837 $164
2025 $1,821 $657 $184–$1,753 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Medtronic, Inc. $13,294 160 payments
  2. Abbott Laboratories $2,317 24 payments
  3. Medtronic USA, Inc. $1,126 47 payments
  4. Boston Scientific Corporation $664 19 payments
  5. TerSera Therapeutics LLC $623 39 payments
  6. Saluda Medical Americas, Inc. $604 29 payments
  7. AbbVie, Inc. $530 31 payments
  8. Teva Pharmaceuticals USA, Inc. $529 31 payments
  9. Pfizer Inc. $437 31 payments
  10. Scilex Pharmaceuticals Inc. $411 25 payments
  11. Other $4,720 218 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $14,506 646 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $8,845 4 payments
  3. Travel and Lodging $1,903 4 payments
Products named General payments · program years 2019–2025
  1. INTELLIS ADAPTIVESTIM $7,746 77 payments
  2. SYNCHROMEDII $4,365 34 payments
  3. Proclaim Family of SCS IPGs $1,999 15 payments
  4. SYNCHROMED $520 24 payments
  5. RESTORE $463 19 payments
  6. INTELLIS $461 19 payments
  7. XTAMPZA $389 26 payments
  8. AJOVY $369 17 payments
  9. Evoke $369 20 payments
  10. QULIPTA $338 21 payments
  11. Other $10,129 500 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 27 drugs

Part D claims

1,213

Median for Interventional Pain Management: 1,220

Drug cost

$45,121

Median for Interventional Pain Management: $39,344

Branded share of claims

32.1%

Median for Interventional Pain Management: 34.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Buprenorphine-Naloxone Buprenorphine Hcl/Naloxone Hcl Brand 34 $9,440
Ajovy Autoinjector Fremanezumab-Vfrm Brand 12 $9,099
Oxycontin Oxycodone Hcl Brand 11 $6,032
Buprenorphine Generic 18 $5,647
Oxycodone Hcl Generic 126 $2,610
Gabapentin Generic 108 $2,243
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 107 $2,144
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 179 $2,041
Morphine Sulfate Er Morphine Sulfate Brand 46 $1,199
Buprenorphine Hcl Generic 24 $846

The 10 drugs with the highest cost, of 27 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 1,476 Part D prescribers listed as Interventional Pain Management; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 92 billing codes

Paid by Medicare

$296,482

Of which drugs: $42,773

Medicare patients

554

Average age 71

Services billed

17,182

348 women, 206 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Arthritis 75%
High blood pressure 68%
Depression 31%
Diabetes 28%
Chronic kidney disease 23%
Ischemic heart disease 21%
COPD 21%
Osteoporosis 18%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg J0702 Office 56 267 $1,424
Injection, hydromorphone, up to 4 mg J1170 Office 15 298 $673
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 71 384 $302
Injection, ketorolac tromethamine, per 15 mg J1885 Office 49 299 $143
Injection, methylprednisolone acetate, 1 mg J1010 Office 19 832 $83
Injection, dexamethasone sodium phosphate, 1 mg J1100 Office 60 640 $55

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 11 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Prialt
  • TerSera Therapeutics LLC $142
$142 — —
ZTLido
  • Scilex Pharmaceuticals Inc. $58
$58 — —
UBRELVY
  • AbbVie, Inc. $43
$43 — —
QULIPTA
  • AbbVie, Inc. $43
$43 — —
XTAMPZA
  • Collegium Pharmaceutical, Inc. $22
$22 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 11 in the dashboard with a free account

Records

654 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Interventional Pain Medicine in Nevada

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record